​

Dianthus Therapeutics Stock (NASDAQ:DNTH)

ForecastRevenueOwnershipFinancialsChart
Dianthus Therapeutics by TradingView

Previous Close

$79.23

52W Range

$13.37 - $86.97

50D Avg

$49.92

200D Avg

$34.58

Market Cap

$3.15B

Avg Vol (3M)

$894.12K

Beta

1.24

Div Yield

-

DNTH Company Profile

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

78

IPO Date

Jun 21, 2018

Website

DNTH Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24
License$2.04M$326.00K

Fiscal year ends in Dec 25 | Currency in USD

DNTH Financial Summary

Dec 25Dec 24Dec 23
Revenue$2.04M$6.24M$2.83M
Operating Income$-177.93M$-101.86M$-48.17M
Net Income$-162.34M$-84.97M$-43.55M
EBITDA$-177.93M$-101.45M$-47.82M
Basic EPS-$-2.55$-8.45
Diluted EPS-$-2.55$-8.45

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
BBOTBridgeBio Oncology Therapeutics Inc.
ELVNEnliven Therapeutics, Inc.
IMTXImmatics N.V.
ATAIAtai Beckley N.V
TSHATaysha Gene Therapies, Inc.
ANABAnaptysBio, Inc.
OCSOculis Holding AG
NKTRNektar Therapeutics
SANASana Biotechnology, Inc.
TRMLTourmaline Bio, Inc.